Market Overview

UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing

Share:
Related ISIS
ISIS Pharma Still Undervalued, Needham Says
Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference
Premarket Biotech Digest: Arrowhead Initiates Dosing, Vertex Orkambi Approval, Insider Sales (Seeking Alpha)

Piper Jaffray reduced its rating on ISIS Pharmaceuticals (NASDAQ: ISIS) from Overweight to Neutral and reduced its price target from $18 to $10.

Piper Jaffray noted, "The FDA just released the briefing documents for KYNAMRO's Endocrinologic and Metabolic Drugs Advisory Committee meeting this Thursday, October 18th. The surprise in the docs has to do with questions #5 and #6 relating to "malignant fibrohistiocytic tumors" as well as "hemangiosarcomas" and "hepatocellular adenomas/ carcinomas" in mice "at clinically relevant exposures." … This represents a significant change in our view of KYNAMRO's safety profile going into the panel on Thursday and lowers the potential likelihood of a positive panel vote."

ISIS Pharmaceuticals closed at $13.15 on Monday.

Latest Ratings for ISIS

DateFirmActionFromTo
Jun 2015NeedhamReiteratesBuy
Jun 2015JP MorganMaintainsNeutral
Mar 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters